Last updated: February 14, 2026
What is the current market status for NDC 25021-0052?
NDC 25021-0052 corresponds to Sovaldi (sofosbuvir), manufactured by Gilead Sciences. It is a direct-acting antiviral used in hepatitis C virus (HCV) treatment. Since its FDA approval in December 2013, Sovaldi has significantly impacted hepatitis C management, shifting toward direct-acting antiviral therapies.
The drug's market share dominated the HCV treatment landscape initially, but competition increased after the introduction of generic formulations and other branded treatments. The global demand has stabilized, with steady declines in pricing due to increased competition, patent expirations, and biosimilar development.
How has pricing evolved for Sovaldi (NDC 25021-0052)?
Original Pricing
On launch, the list price for a 12-week course of Sovaldi was approximately $84,000. The high initial cost reflected treatment efficacy and the lack of alternative options.
Price Trends
- 2014-2016: The average wholesale price (AWP) hovered around $84,000 for a standard course. Promotional discounts and negotiated rebates brought actual payer costs lower.
- 2017-2020: Prices declined to approximately $54,000-$60,000, driven by competition, patent uncertainties, and payer negotiations.
- 2021-2023: Market entry of generics decreased list prices further, with some formulations available at $24,000-$30,000 per course in certain regions or through negotiated discounts.
Impact of Generics
India's patent challenges and subsequent patent expirations of Gilead's Sovaldi have led to generic versions with substantially reduced prices. For example, Indian generics are priced as low as $900-$1,200 per treatment course.
What is the current market projection?
Market Volume
The global market for hepatitis C treatments was valued at approximately $20 billion in 2018, with Sovaldi comprising a significant share initially. The volume has decreased as treatment guidelines shifted towards shorter, more tolerable regimens.
Future Pricing Trends
- The global hepatitis C treatment market is expected to decline by CAGR of 4-6% from 2023 to 2028 due to lower uptake, patent expirations, and simplification of treatment protocols.
- Generic and biosimilar entry will continue pressuring prices downward.
- Pricing in emerging markets is increasingly driven by local regulatory policies, with prices often set below $5,000 per course.
Regional Variations
- United States: Average treatment costs are higher, partly due to insurance negotiations and high drug list prices.
- India, Africa, Southeast Asia: Prices are significantly lower, often under $1,000, driven by local manufacturing and procurement policies.
- European Union: The market prices range from €20,000-€50,000 per treatment, depending on country negotiations and reimbursement policies.
How do pricing strategies affect market penetration?
- Payer Negotiations: Large insurers and government programs negotiate discounts and rebates, lowering actual costs below list prices.
- Patent Status: Market competitiveness increases as patents expire or face legal challenges, enabling lower-cost generics.
- Regulatory Policies: Countries with strict cost-effectiveness assessments tend to negotiate lower prices to approve newer regimens, reducing overall segment prices.
Key Takeaways
- Initial list price for Sovaldi was ~$84,000 per course; actual payer costs often significantly lower due to discounts.
- Market volume peaked early following launch but has declined due to new treatment options and generic competition.
- Price projections indicate continued decline, especially in emerging markets and with generic availability.
- Regional pricing varies widely, with developed countries maintaining higher costs compared to emerging markets.
- Market dynamics are heavily influenced by patent status, regulatory policies, and competition from biosimilars and generics.
FAQs
1. Will the price of Sovaldi increase or decrease in the future?
Prices are expected to decrease further due to generic competition and broader use of less expensive treatments.
2. What factors influence the pricing variations across regions?
Regulatory policies, patent status, market size, and local economic factors primarily influence regional price differences.
3. How much can payers save via negotiated discounts?
Rebates and discounts commonly reduce actual costs by 20% to 60% from list prices in the U.S.
4. Are new hepatitis C treatments replacing Sovaldi?
Yes. Newer, shorter regimens with similar or improved efficacy have gained market share, further pressuring Sovaldi’s market share and price.
5. What is the potential impact of biosimilars on Sovaldi’s market?
Biosimilars being approved and adopted will likely reduce the treatment costs further, especially in markets with cost sensitivity.
References
- Gilead Sciences, Sovaldi prescribing information (2013).
- IQVIA. Global hepatitis C market report (2022).
- World Health Organization. Hepatitis C virus overview (2022).
- Healthcare Regulatory Authority reports.
- Indian Patent Office. Patent status and generic approval data (2023).
